Table 1.

Overview of the immune monitoring results

Peptide-specific immune respones					September 13, 2018 (V9)		March 14, 2019 (V17)		July 08, 2019 (post V18)
No.	Peptide sequence	Gene and somatic variant	HLA	VAF (%)	CD4	CD8	CD4	CD8	CD4	CD8
1	HSYRGTGGIFK	TBL1XR1 NM_024665 c.G1462A:p.E488K	HLA-A*03:01	36	–	–	++ SI: 4.3 (1.7%)	+ SI: 2.1 (0.6%)	Pool peptide 1+5 +++ SI: 7.3 (0.4%)	Pool peptide 1+5 ++++ SI: 15.9 (6.5 %)
2	MMFRNYQRK	CHD4 NM_001273 c.G1705A:p.V569M	HLA-A*03:01	38	–	–	–	++ SI: 3.8 (1,8%)	–	+ SI: 3.2 (0.6 %)
3	EVSAAHRAHYF	DNMT3A NM_022552.4 c.G2375A:p.R792H	HLA-A*26:01	36	+++ SI: 7.7 (1.1%)	(+) positive tendency	+ SI: 2.2 (0.6%)	–	Pool peptide 3+7 ++++ SI: 21.6 (1.8%)	Pool peptide 3+7 –
4	DPTASVPSM	KIAA1549 NM_001164665 c.G4753A:p.V1585M	HLA-B*35:01	33	+++ SI: 5.6 (4.3%)	–	++ SI: 3.7 (1.6%)	–	Pool peptide 4+6 ++++ SI: 11.6 (0.5%)	Pool peptide 4+6 –
5	HIPIIWATSY	PIK3C2B NM_002646 c.G1919A:p.R640H	HLA-A*26:01	45	–	–	++++ SI: 13.1 (6,6%)	+++ SI: 6.2 (2.9%)	Pool peptide 1+5 +++ SI: 7.3 (0.4%)	Pool peptide 1+5 ++++ SI: 15.9 (6.5 %)
6	VQRRAQGKLF	KEL NM_000420 c.A869T:p.E290V	HLA-B*15:01	37	–	–	–	+ SI: 2.1 (1.0%)	Pool peptide 4+6 ++++ SI: 11.6 (0.5)	Pool peptide 4+6 –
7	AFDDKTRLV	WWC3 NM_015691 c.T662C:p.V221A	HLA-C*04:01	33	–	–	–	–	Pool peptide 3+7 ++++ SI: 21.6 (1.8%)	Pool peptide 3+7 –
8	TGVPQSRPHIPRTQPQP	RNF43 NM_017763.4 c.C1742A:p.P581H	Class II	36	++++ SI: 39.3 (1.7%)	–	+ SI: 2.5 (0.7%)	–	++ SI: 4.1 (0.3 %)	–
9	MFKGVASSQFLPKGTKT	SETD2 NM_014159.6 c.G158A:p.R53Q	Class II	38	++++ SI: 37.5 (0.9%)	–	+++ SI: 9.5 (2.0%)	–	++++ SI: 35.9 (2.4%)	–
10	DWNPHQDLHAQDRAHRI	SMARCA4 NM_001128844.1 c.A3555T:p.Q1185H	Class II	33	–	–	–	–	–	–

HLA: human leukocyte antigen type, for which binding was predicted. VAF: variant allele frequency, detection frequency of the mutated allele. The observed frequencies could be influenced by tumor content and copy number variations and do not directly equal the proportion of the mutation in the tumor. SI: Stimulation Index, x-fold increase of polyfunctional reactive T cells (at least two of the markers CD154, IFN-γ, TNF and/or IL-2 positive) in the stimulated specimen compared to the according negative control specimen. Additional information: proportion (%) of reactive T cells (IFN-γ, TNF, IL-2 and/or CD154 positive) of the CD4⁺ or CD8⁺ T cell population after in vitro amplification. Does not directly equal the frequency of specific cells in vivo. +, lightly positive; ++, positive; +++, strongly positive; ++++, very strongly positive; IFN, interferon; TNF, tumor necrosis factor; IL, interleukin.